Literature DB >> 15083780

Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

Robert S Stern1, Tamar Nijsten, Steven R Feldman, David J Margolis, Tara Rolstad.   

Abstract

The impact of psoriasis on quality of life has been studied in select patient populations. Population-based data detailing the distribution of extent of disease, associated problems in everyday life, and treatment satisfaction for the US population have been lacking. Our population-based survey indicates that approximately 4.5 million adults have been diagnosed as having psoriasis. Most (59%) have little or no involvement, but 650,000 adults have at least three palms of body surface involved and more than 1,000,000 indicate substantial dissatisfaction with their treatment. Only 5% of patients (56,000) who report severe dissatisfaction with current therapy have extensive disease (10 palms). Many individuals with little psoriasis at the time of interview considered the disease to be a large problem in everyday life.

Entities:  

Mesh:

Year:  2004        PMID: 15083780     DOI: 10.1046/j.1087-0024.2003.09102.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  148 in total

1.  The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

2.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

Review 3.  Clinical and histologic diagnostic guidelines for psoriasis: a critical review.

Authors:  Mary Ann N Johnson; April W Armstrong
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 4.  Psoriasis and its management.

Authors:  Catherine H Smith; J N W N Barker
Journal:  BMJ       Date:  2006-08-19

5.  Depression and the risk of psoriasis in US women.

Authors:  P L Dominguez; J Han; T Li; A Ascherio; A A Qureshi
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-10-03       Impact factor: 6.166

Review 6.  Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.

Authors:  Michael Zakrewsky; Sunny Kumar; Samir Mitragotri
Journal:  J Control Release       Date:  2015-09-15       Impact factor: 9.776

Review 7.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.

Authors:  Emmilia A Dowlatshahi; Marlies Wakkee; Lidia R Arends; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

8.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.

Authors:  Ji Sun van Bezooijen; Deepak M W Balak; Martijn B A van Doorn; Caspar W N Looman; Marco W J Schreurs; Birgit C P Koch; Teun van Gelder; Errol P Prens
Journal:  Dermatology       Date:  2016-09-01       Impact factor: 5.366

10.  Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis.

Authors:  E D Dommasch; D B Shin; A B Troxel; D J Margolis; J M Gelfand
Journal:  Br J Dermatol       Date:  2009-11-10       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.